Case Report
Primary Intracranial Synovial Sarcoma

Mohit Patel, Luyuan Li, Ha Son Nguyen, Ninh Doan, Grant Sinson, and Wade Mueller

Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Correspondence should be addressed to Ha Son Nguyen; hsnguyen@mcw.edu

Received 22 March 2016; Accepted 20 April 2016

Academic Editor: Norman S. Litofsky

Copyright © 2016 Mohit Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Synovial sarcoma is an aggressive soft tissue sarcoma with uncertain histological origin. Its trademark is a unique t(X;18)(p11.2;q11.2) chromosomal translocation resulting in SYT-SSX fusion protein. The pathology frequently presents as a localized disease, especially near large joints around the knee and thigh [1]. Intracranial disease, which is rare, has been reported as metastasis from synovial sarcoma. We report a case with no obvious primary extracranial pathology, suggesting primary intracranial disease; this has not been reported in the literature.

Case Description. A 21-year-old male, with a prior right skull lesion resection for atypical spindle cell neoplasm, presented with headaches, gait instability, left arm weakness, and left homonymous hemianopsia. CT of head demonstrated a right parietal hemorrhagic lesion with mass effect, requiring surgical decompression. Histopathology revealed synovial sarcoma. FISH analysis noted the existence of the t(X;18)(p11.2;q11.2) chromosomal translocation. PET scan did not show other metastatic disease. He underwent stereotactic radiotherapy and adjuvant chemotherapy. At 2-year follow-up, he remained nonfocal without recurrence. Conclusion. We report the first known case of primary intracranial synovial sarcoma. Moreover, we stress that intracranial lesions may have a tendency for hemorrhage, requiring urgent lifesaving decompression.

1. Background

Synovial sarcoma is an aggressive soft tissue sarcoma with uncertain histological origin. Its trademark is a unique t(X;18)(p11.2;q11.2) chromosomal translocation resulting in SYT-SSX fusion protein. The pathology frequently presents as a localized disease, especially near large joints around the knee and thigh [1]. Intracranial disease, which is rare, has been reported as metastasis from synovial sarcoma [1–8]. We report a case with no obvious primary extracranial pathology, suggesting primary intracranial disease; this has not been reported in the literature.

2. Case Presentation

A 21-year-old male presented with persistent headaches. CT of head showed a right parietal lobulated skull lesion with intracranial extensions. The lesion was subsequently resected and diagnosed as atypical spindle cell neoplasm. Eight months later, patient presented to the emergency room with headaches, gait instability, and left arm weakness. Physical examination revealed left homonymous hemianopsia, left hand weakness, and ataxia. Patient could not tolerate MRI due to agitation. CT of head demonstrated a right parietal heterogeneous, hyperdense mass with a large medial hematoma. Due to increased agitation, repeat CT of head was completed 8 hours later, which showed worsening midline shift to 9 mm (Figure 1). Patient was taken to the operating room emergently for decompression and clot evacuation. The mass was friable and hemorrhagic. Postoperatively, patient's visual field gradually improved and left hand weakness resolved. He was discharged home 3 days later. Histopathology was consistent with synovial sarcoma. FISH analysis noted the existence of the t(X;18)(p11.2;q11.2) chromosomal translocation. PET scan did not show any other metastatic disease.

One month after discharge, the patient underwent stereotactic radiotherapy (60 Gy in 30 fractions) for local tumor control. Three weeks after completion of radiotherapy, he had another operation for excision of the residual tumor and cranioplasty. Intraoperatively, multiple lobulated cysts were seen and removed. Gross total resection of the tumor was achieved; a wire mesh was placed over the right parietal bony defect. The patient recovered quickly and went home on postoperative day 3. Two months later, the patient received 3 cycles of adjuvant chemotherapy (AIM regimen) consisting
of doxorubicin (adriamycin), ifosfamide, and mesna. Since then, the patient has been followed up closely in the clinic with MRI scans every 3 months. He continued to be neurologically intact without any evidence of tumor recurrence two years after the chemotherapy.

3. Discussion

Sarcoma is generally categorized into bone and soft tissue sarcoma. Synovial sarcoma is a type of soft tissue sarcoma that occurs mainly in adolescents and young adults between the ages of 15 and 30 years, with a slight male predominance [1, 10]. The neoplasm constitutes 5 to 10% of the soft tissue sarcomas [1, 2]. There are four subtypes of synovial sarcoma: monophasic, monophasic epithelial, biphasic, and poorly differentiated [1, 11]. The term “synovial sarcoma” was introduced in 1934 due to similarities with synovial tissue under light microscopy [1]. However, subsequent immunohistochemical and ultrastructural studies demonstrated that tumor cells do not share characteristics with normal synovium [12]. Moreover, cDNA-microarray based studies suggest a close linkage between synovial sarcoma and neural crest-derived malignant peripheral nerve sheath tumor [10, 13]. Other studies also indicate that a human multipotent mesenchymal stem cell can function as a cell of origin [14].

Similar to other soft tissue sarcomas, the most common initial symptom of synovial sarcoma is an enlarging soft tissue mass [4]. Frequently seen near large joints, synovial sarcoma may also arise primarily in a wide variety of organs, including kidney [15], heart [16], and lung [1]. A small minority of patients develop symptoms secondary to metastatic lesions prior to diagnosis of the primary pathology, largely complaints related to lung metastases [4, 10]. The rate for metastatic disease in synovial sarcoma ranges up to 33% [4, 17]. Common sites of metastasis include lung, bone, and lymph nodes [2, 10]. Intracranial disease, which is rare, has been reported as metastasis from synovial sarcoma. These are summarized in Table 1. Of the available data on six cases with intracranial metastases, one exhibited a left soft tissue mass without neurologic symptoms [2], one demonstrated sensory aphasia [9], and two patients exhibited headaches/vomitus [4, 5]; for the remaining two cases, the symptoms were not clear based on review of the pertinent articles [1, 3]. Our patient presented with a right skull lesion with intracranial extension and headaches; his recurrence was associated with neurologic deficits and a hemorrhagic tumor with significant mass effect. Along with the case by Przkora et al. [4], this is the second instance that documents intracranial hemorrhage associated with synovial sarcoma. Unlike prior cases, this case highlights intracranial disease without obvious primary extracranial pathology, suggesting primary intracranial disease.

The standard treatment for local synovial sarcoma is surgical resection with wide margins [1]. Adjuvant therapies, including radiation and chemotherapy, have demonstrated benefits for local recurrence and prognosis [3]. Treatment for metastatic intracranial disease has not been optimized. Siegel et al. [2] reported a patient with a skull lesion that appeared to respond to neoadjuvant chemotherapy and external beam radiation; there was no evidence of recurrence in the cranial region at the time of the patient's death (he succumbed to pulmonary and intra-abdominal metastases). Kaufman and Tsukada [5] reported a patient with cerebral metastasis to the right cerebellum who was treated with radiation and documented complete remission; the patient passed away from pulmonary metastases; however, at the time of autopsy residual tumor was found in the brain [5]. Nuwal et al. [1] mentioned that their patient had chemotherapy with temozolamide and radiation to the skull; the effectiveness of the treatment was unclear, as the patient succumbed 6 months later due to pleural effusion/ascites/anasarca. Flannery et al. [6] described a patient who passed away 1 month after her diagnosis of brain metastases after receiving surgical resection followed by gamma knife. Grossman and Ram [7] reviewed 21 patients with intracranial metastases from sarcoma, including 4 with synovial sarcoma; their patients received surgical resection, whole brain radiation, and/or
| Literature        | Year | Age | Gender | Primary                   | Symptoms at presentation       | Intracranial findings | Other sites of metastases                      | Outcome     |
|-------------------|------|-----|--------|----------------------------|--------------------------------|------------------------|-----------------------------------------------|-------------|
| Flannery et al. [6] | 2010 | 26  | F      | Knee                       | Hemiparesis                  | * * *                 | * * *                                         | Survival 1   |
| Kaufman and Tsukada [5] | 1976 | 32  | M      | Right foot                 | Headaches, vomiting, ataxia  | Right cerebellar mass  | Lung, “numerous subcutaneous masses”          | Survival 7   |
| Nuwal et al. [1]   | 2012 | 35  | M      | Left lung                  | * * *                        | Left parietooccipital mass | None                                          | Survival 6   |
| Otani et al. [9]   | 2013 | 41  | F      | Left inguinal region       | Sensory aphasia              | Left frontal, parietal, parietotemporal right frontal mass with hemorrhage | * * *          | * * *                                |
| Przkora et al. [4] | 2003 | 74  | F      | Right popliteal mass       | Headaches, vomiting          | Left soft tissue mass, otherwise no neurologic symptoms | Lung            | Survival 11 year                     |
| Siegel et al. [2]  | 2008 | 17  | M      | Right thigh                | Left skull mass              | Femur, buttock, intra-abdominal, lung | Survival 2 years                             |             |
| Our case           | 2015 | 21  | M      | Right skull lesion with intracranial extension | Headaches, ataxia, left hemianopsia left arm weakness | Right parietal mass with hemorrhage | None                                         | At least 2 years |
stereotactic radiosurgery; median overall survival was 7 months. Three additional cases did not comment on adjuvant therapy after surgical treatment [3, 4, 8] and one [9] was not available in English. Given the paucity of clinical data available regarding this deadly disease, it is vital to collect and report as much clinical information as possible so this disease can be further dissected, which ultimately will help to devise new therapies.

4. Conclusion

Synovial sarcoma is a malignant neoplasm. Rare instances of intracranial disease have been attributed to metastasis. Our patient is the first known case of intracranial disease without obvious primary extracranial pathology, suggesting that the primary disease arose from the brain. We also noted the hemorrhagic complication associated with brain lesions. In the case of sudden neurological deterioration, it is important to be cognizant of the tendency for intracranial lesions to hemorrhage, requiring urgent lifesaving decompression.

Competing Interests

The authors declare that they have no competing interests.

References

[1] P. Nuwal, R. Dixit, N. S. Shah, and A. Samaria, “Primary monophasic synovial sarcoma lung with brain metastasis diagnosed on transthoracic FNAC: report of a case with literature review,” Lung India, vol. 29, no. 4, pp. 384–387, 2012.

[2] H. J. Siegel, W. H. Dunahm, R. Lopez-Ben, and G. P. Siegal, “Intracranial metastasis from synovial sarcoma,” Orthopedics, vol. 31, no. 4, article 405, 2008.

[3] A. M. Baptista, O. P. de Camargo, A. T. Croci et al., “Synovial sarcoma of the extremities: prognostic factors for 20 nonmetastatic cases and a new histologic grading system with prognostic significance,” Clinics, vol. 61, no. 5, pp. 381–386, 2006.

[4] R. Przkora, P. Vogel, O. W. Ullrich, R. Knüchel, K. W. Jauch, and U. Bolder, “Synovial sarcoma—unusual presentation with cerebral hemorrhage,” Archives of Orthopaedic and Trauma Surgery, vol. 123, no. 7, pp. 376–378, 2003.

[5] J. Kaufman and Y. Tsukada, “Synovial sarcoma with brain metastases. Report of a case responding to supravoltage irradiation and review of the literature,” Cancer, vol. 38, no. 1, pp. 96–99, 1976.

[6] T. Flannery, H. Kano, A. Niranjan et al., “Gamma knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 2, pp. 513–519, 2010.

[7] R. Grossman and Z. Ram, “Recursive partitioning analysis (RPA) classification predicts survival in patients with brain metastases from sarcoma,” World Neurosurgery, vol. 82, no. 6, pp. 1291–1294, 2014.

[8] S. Yoshida, K. Morii, M. Watanabe, T. Saito, F. F. Lang, and R. Sawaya, “Brain metastasis in patients with sarcoma: an analysis of histological subtypes, clinical characteristics, and outcomes,” Surgical Neurology, vol. 54, no. 2, pp. 160–164, 2000.

[9] Y. Otani, T. Ichikawa, K. Kurozumi et al., “A case of synovial sarcoma with brain metastasis treated with surgical resection and stereotactic radiosurgery,” No Shinkei Geka, vol. 41, no. 3, pp. 255–262, 2013.

[10] R. Rong, E. E. Doxtader, J. Tull, G. de la Roza, and S. Zhang, “Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 2, pp. 217–221, 2010.

[11] A. Rajwanshi, R. Srinivas, and G. Upasana, “Malignant small round cell tumors,” Journal of Cytology, vol. 26, no. 1, pp. 1–10, 2009.

[12] M. Miettinen and I. Virtanen, “Synovial sarcoma—a misnomer,” The American Journal of Pathology, vol. 117, no. 1, pp. 18–25, 1984.

[13] S. Nagayama, T. Katagiri, T. Tsunoda et al., “Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray,” Cancer Research, vol. 62, no. 20, pp. 5859–5866, 2002.

[14] N. Naka, S. Takenaka, N. Araki et al., “Synovial sarcoma is a stem cell malignancy,” STEM CELLS, vol. 28, no. 7, pp. 1119–1131, 2010.

[15] V. Radhakrishnan, M. Dhanushkodi, K. Narayanswamy, A. Raja, S. Sundersingh, and T. Sagar, “Synovial sarcoma of kidney in a child: a rare presentation,” Journal of Indian Association of Pediatric Surgeons, vol. 21, no. 2, pp. 75–77, 2016.

[16] E. Prifti, A. Vedshi, M. Ikonomi, and A. Demiraj, “Primary cardiac synovial sarcoma originating from the mitral valve causing left ventricular outflow tract obstruction,” World Journal for Pediatric & Congenital Heart Surgery, vol. 6, no. 4, pp. 650–653, 2015.

[17] J. J. Lewis, C. R. Antonescu, D. H. Y. Leung et al., “Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity,” Journal of Clinical Oncology, vol. 18, no. 10, pp. 2087–2094, 2000.